




AACR

American Association
for Cancer Research®

GLIO-1 is a selective DHODH inhibitor with preclinical activity in IDH-mutant gliomas and KDM6-mutated cancer models

Diana D. Shi, M.D.

Massachusetts General Brigham, Harvard Medical School

Boston, MA, USA

AACR DRUG DISCOVERY AND DEVELOPMENT (AACR D3)

July 21-24, 2026 | Sheraton Boston Hotel | Boston, MA

Disclosure Information




Diana Shi

I have no financial relationships to disclose.

D. Nash, D. Vitt, C. Gege, H. Kohlhof are co-authors on this abstract. D. Nash, D. Vitt, and H. Kohlhof are co-founders of Gliomic Therapeutics. H. Kohlhof, D. Vitt, and C. Gege are employees of Immunic Therapeutics.


Preclinical efficacy data using GLIO-1 are shown in this presentation. GLIO-1 is an investigational compound. All data presented are preclinical. Safety and efficacy in humans have not been established.

Preclinical models of IDH-mutant gliomas are sensitive to replication stress caused by DHODH inhibitors



Shi et al., *Cancer Cell* 2022, PMID:3598343

The DHODH inhibitor GLIO-1 preferentially kills IDH-mutant cells in preclinical models and is on-target




Tsai et al., *bioRxiv* 2026, PMID: 42039522


GLIO-1 displays improved monotherapy efficacy and no weight loss in preclinical studies compared to BAY 2402234 (Orludodstat), a leading clinical-stage DHODHi



MGG152 (IDH-mut)
orthotopic xenografts





Naïve C57BL/6 mice






Tsai et al., *bioRxiv* 2026

Sensitivity of IDH-mutant gliomas to replication stress is due to inhibition of KDM6 enzymes



KDM6-mutant bladder cancer models recapitulate sensitivity of IDH-mutant glioma models to DHODHi



Tsai et al., *bioRxiv* 2026, PMID: 42039522

Conclusions



- GLIO-1 is an on-target DHODHi that displays preclinical activity in IDH-mutant gliomas and KDM6-mutant bladder cancers, supporting further evaluation for translation to clinical testing.
- KDM6 activity is a determinant of replication stress sensitivity and a potential pan-cancer, mechanism-based biomarker of DHODHi efficacy.

Acknowledgements



Samuel K. McBrayer
William G. Kaelin, Jr

Mass General Brigham:

Alex C.-Y. Tsai
Mathew Lin
Christina Zheng
Jongchan Park
Dorothy Junginger
Daniel Cahill

U. Pittsburgh:

Kalil Abdullah



hhmi
Howard Hughes
Medical Institute

Gliomic/Immunic:

Duane Nash

Hella Kohlhof
Daniel Vitt
Christian Gege
Keith Flaherty

UT Southwestern:

Vinesh T. Puliappadamba
Milan Savani
Bingbing Li

BURROUGHS
WELLCOME
FUND 

GLIOMIC
Therapeutics



LUBIN FAMILY
FOUNDATION

Dana-Farber:

Julie Losman
Victoria Donovan
Kent Mouw

Broad Institute:

John Doench
Eleanor Kaplan
Laura Drepanos



**NATIONAL
CANCER
INSTITUTE**